Antiviral Drugs - Botswana

Botswana

The projected revenue for the Antiviral Drugs market in Botswana is estimated to reach US$3.92m in 2024.
It is expected that the revenue will experience an annual growth rate (CAGR 2024-2029) of 2.20%, leading to a market volume of US$4.37m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the market, with an estimated value of US$30,640.00m in 2024.
Botswana's pharmaceutical market is experiencing a growing demand for antiviral drugs due to the increasing prevalence of viral infections in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Botswana has seen significant growth in recent years.

Customer preferences: The demand for Antiviral Drugs in Botswana has been driven by the increasing prevalence of viral infections such as HIV, hepatitis B, and C. Additionally, the government's efforts to provide affordable healthcare services have also contributed to the growth of the market.

Trends in the market: The Antiviral Drugs market in Botswana has been experiencing a shift towards generic drugs due to their lower cost compared to branded drugs. This has been aided by the government's efforts to promote the use of generic drugs in the country.

Local special circumstances: Botswana has one of the highest HIV prevalence rates in the world, with an estimated 20.3% of the adult population living with the virus. This has led to a significant demand for Antiviral Drugs in the country. Additionally, the government's efforts to provide free Antiviral Drugs to HIV-positive individuals have also contributed to the growth of the market.

Underlying macroeconomic factors: Botswana's economy has been growing steadily in recent years, with a GDP growth rate of 4.3% in 2019. This has led to an increase in disposable income, which has in turn contributed to the growth of the Antiviral Drugs market. Additionally, the government's efforts to improve healthcare services in the country have also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.